From: Estimation of HPV prevalence in young women in Scotland; monitoring of future vaccine impact
Urine | Self-taken swab | LBC | ||||
---|---|---|---|---|---|---|
HPV type | Prevalence | 95% CI | Prevalence | 95% CI | Prevalence | 95% CI |
Any HPV | 32.2% | (27.4, 37.0)% | 39.5% | (34.2, 44.9)% | 49.4% | (47.2, 51.5)% |
HPV 16 or 18 | 10.0% | (6.8, 13.1)% | 16.6% | (12.5, 20.7)% | 23.0% | (21.2, 24.8)% |
HPV 31 or 33 or 45 or 51 | 9.3% | (6.4, 12.3)% | 13.5% | (9.7, 17.3)% | 19.1% | (17.4, 20.8)% |
Any high-risk HPV | 19.1% | (15.0, 23.1)% | 29.1% | (24.1, 34.1)% | 41.2% | (39.1, 43.4)% |
High-risk excluding HPV 16 or 18 | 13.2% | (9.8, 16.7)% | 20.6% | (16.2, 25.0)% | 32.3% | (30.2, 34.3)% |
High-risk excluding HPV 16, 18, 31, 33, 45 or 51 | 8.0% | (5.2, 10.8)% | 11.2% | (7.7, 14.7)% | 21.5% | (19.7, 23.2)% |